MARKET

MTNB

MTNB

Matinas Biopharm
AMEX
0.6280
-0.0056
-0.89%
Pre Market: 0.6438 +0.0158 +2.52% 06:22 07/07 EDT
OPEN
0.6150
PREV CLOSE
0.6336
HIGH
0.6395
LOW
0.6150
VOLUME
598
TURNOVER
0
52 WEEK HIGH
3.090
52 WEEK LOW
0.4800
MARKET CAP
4.02M
P/E (TTM)
-0.3276
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MTNB last week (0629-0703)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at MTNB last week (0622-0626)?
Weekly Report · 06/29 10:19
Matinas BioPharma Receives Additional NYSE Notice Of Non-Compliance; Compliance Plan Accepted
NASDAQ · 06/29 06:20
Matinas BioPharma Granted NYSE American Compliance Extension
TipRanks · 06/26 21:52
Matinas BioPharma faces NYSE notice over equity shortfall; gets until 2027 to comply
Seeking Alpha · 06/26 21:38
Matinas BioPharma receives noncompliance notification from NYSE
TipRanks · 06/26 21:20
Weekly Report: what happened at MTNB last week (0615-0619)?
Weekly Report · 06/22 10:28
More
About MTNB
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Webull offers Matinas BioPharma Holdings Inc stock information, including AMEX: MTNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTNB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTNB stock methods without spending real money on the virtual paper trading platform.